Ionis Pharmaceuticals Inc (NASDAQ: IONS)’s stock price has decreased by -0.77 compared to its previous closing price of 34.96. However, the company has seen a -5.04% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2024-12-23 that Ionis Pharmaceuticals applies proprietary antisense technology to tackle diseases at their genetic source, focusing on conditions such as FCS, Angelman syndrome, and HAE. The FDA approval of Tryngolza for FCS positions Ionis as the first company to independently develop and launch an RNA-targeted therapy. Ionis forecasts that its pipeline, containing approximately 40 investigational drugs, could generate billions in peak sales, with four launches projected in the next three years.
Is It Worth Investing in Ionis Pharmaceuticals Inc (NASDAQ: IONS) Right Now?
The 36-month beta value for IONS is also noteworthy at 0.36. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 4 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IONS is 145.55M, and at present, short sellers hold a 7.23% of that float. The average trading volume of IONS on January 03, 2025 was 1.43M shares.
IONS’s Market Performance
IONS’s stock has seen a -5.04% decrease for the week, with a -3.91% drop in the past month and a -11.91% fall in the past quarter. The volatility ratio for the week is 2.82%, and the volatility levels for the past 30 days are at 3.78% for Ionis Pharmaceuticals Inc The simple moving average for the last 20 days is -5.36% for IONS stock, with a simple moving average of -16.76% for the last 200 days.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with BMO Capital Markets repeating the rating for IONS by listing it as a “Market Perform.” The predicted price for IONS in the upcoming period, according to BMO Capital Markets is $60 based on the research report published on August 02, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see IONS reach a price target of $62, previously predicting the price at $53. The rating they have provided for IONS stocks is “Outperform” according to the report published on July 24th, 2024.
Jefferies gave a rating of “Buy” to IONS, setting the target price at $75 in the report published on July 16th of the previous year.
IONS Trading at -6.23% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.28% of loss for the given period.
Volatility was left at 3.78%, however, over the last 30 days, the volatility rate increased by 2.82%, as shares sank -3.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.05% lower at present.
During the last 5 trading sessions, IONS fell by -5.04%, which changed the moving average for the period of 200-days by -17.46% in comparison to the 20-day moving average, which settled at $36.66. In addition, Ionis Pharmaceuticals Inc saw -0.77% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IONS starting from Hayden Michael R, who purchase 5,000 shares at the price of $36.22 back on Dec 23 ’24. After this action, Hayden Michael R now owns 35,219 shares of Ionis Pharmaceuticals Inc, valued at $181,079 using the latest closing price.
Swayze Eric, the EVP Research of Ionis Pharmaceuticals Inc, sale 1,194 shares at $37.92 during a trade that took place back on Nov 12 ’24, which means that Swayze Eric is holding 33,713 shares at $45,278 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -0.46 for the present operating margin
- 0.97 for the gross margin
The net margin for Ionis Pharmaceuticals Inc stands at -0.45. The total capital return value is set at -0.13. Equity return is now at value -73.33, with -11.92 for asset returns.
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.66 points at debt to capital in total, while cash flow to debt ratio is standing at -0.28. The debt to equity ratio resting at 1.93. The interest coverage ratio of the stock is -4.34.
Currently, EBITDA for the company is -230.01 million with net debt to EBITDA at -4.4. When we switch over and look at the enterprise to sales, we see a ratio of 8.2. The receivables turnover for the company is 44.8for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.91.
Conclusion
In summary, Ionis Pharmaceuticals Inc (IONS) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
